Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas
Sameer Mir, Abhilash Venugopalan, Jingli Zhang, Nishanth Ulhas Nair, Manjistha Sengupta, Manakamana Khanal, Chaido Stathopoulou, Qun Jiang, Raffit Hassan · 2024
Read Persistence of activated anti‐mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas by Sameer Mir, Abhilash Venugopalan, Jingli Zhang, Nishanth Ulhas Nair, Manjistha Sengupta, Manakamana Khanal, Chaido Stathopoulou, Qun Jiang, Raffit Hassan (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11567854.txt.
Description
A peer-reviewed research article from Europe PMC (2024). Patients with advanced gastric and colorectal cancers have limited treatment options. Since mesothelin is highly expressed in these tumour types, we evaluated the therapeutic benefits of anti‐mesothelin hYP218 CAR T cells alone, and in combination with anti‐PD1 antibody, pembrolizumab.GEPIA analysis was performed using human gastric (n = 408) and colon cancer tumours (n = 275) in TCGA database, to evaluate mRNA expression of mesothelin, compared to normal tissues.
Catalog record
| CREATOR | Sameer Mir, Abhilash Venugopalan, Jingli Zhang, Nishanth Ulhas Nair, Manjistha Sengupta, Manakamana Khanal, Chaido Stathopoulou, Qun Jiang, Raffit Hassan |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |